TempraMed Technologies Ltd.

Integrated smart technology builds on TempraMed’s proven VIVI platform, providing robust Temperature control with  medication management for individuals using life-saving medication Highlights:  Expands TempraMed’s product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost  every insulin and GLP-1 pens to...

New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B customers to address the forecasted increased demand for products Highlights:  -          Manufacturing site in Florida expands TempraMed’s U.S. production footprint-          Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers-          Shortens delivery...

Highlights -          Newly granted patent protects TempraMed’s VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture-          Expands the Company’s ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics-          Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia’s premium...

A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership. Vancouver, BC – December 10, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr....

Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI...

Vancouver, BC – December 5, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company...

-          Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction -          Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance -          One of many distribution...

-          Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz -          Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond and more-          Strategic agreement supports TempraMed’s global shift from online B2C to major pharmacy networks and B2B medical payors-          Distribution to over 2,500 outlets including pharmacy chains, supermarkets,...